Bank of America Securities analyst Alec Stranahan has reiterated their bullish stance on KRYS stock, giving a Buy rating yesterday.
Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Alec Stranahan has given his Buy rating due to a combination of factors that highlight Krystal Biotech’s strong growth potential and promising future developments. The company’s revenue for 2024 has met expectations, and the successful launch of Vyjuvek with increasing gross margins and broad insurance coverage has solidified confidence in its performance.
Additionally, upcoming pipeline catalysts, particularly in the herpes simplex virus (HSV) platform, are expected to generate significant value as they progress. The focus on expanding markets with anticipated approvals in the EU and Japan in 2025, alongside advancements in the ophthalmologic and dermatology franchises, underscores a diversified growth strategy that supports the Buy recommendation with an elevated price objective.
KRYS’s price has also changed moderately for the past six months – from $198.690 to $176.170, which is a -11.33% drop .